Home » Business » [2020 10대 뉴스-의료/제약(下)]’Public mask’ upheaval in Corona 19… Pharmaceutical and bio industry’storm growth’, etc.

[2020 10대 뉴스-의료/제약(下)]’Public mask’ upheaval in Corona 19… Pharmaceutical and bio industry’storm growth’, etc.

【Youth Daily】 2020 is the year when most industries fell into great chaos due to the global novel coronavirus infection (Corona 19).

The atmosphere of the medical and pharmaceutical industry was not very different. The government and the medical community have put all their efforts into preventing the spread of Corona 19 and preventing the spread, and the pharmaceutical industry as a whole has shown its participation in this movement.

In the early days of the spread of Corona 19, most pharmacies actively tried to prevent the spread of Corona 19 by selling public masks amid the mask crisis. Some pharmaceutical and bio companies have also jumped into the development of treatments and vaccines to overcome Corona 19.

Unlike other industries that have experienced an endless crash throughout the year, the pharmaceutical and bio industry has not only achieved a step-up growth with a number of bio-ventures listed on the list of listed companies, but also steadily achieved the export of technology in the pipeline, causing the Corona 19 shock. It was also evaluated that he had stepped back from.

At the end of 2020, the Youth Daily selected and organized the top 10 news issues that hit the medical/pharmaceutical industry this year.

① Corona 19 covering the whole world… Pharmaceutical industry is also’emergency’
② Corona 19 vaccine and treatment development’active’
③ Flu vaccine exposed to room temperature… National vaccination’temporary suspension’
④ Medical industry, general strike after 6 years… Twice’group leave’
⑤ Ministry of Food and Drug Safety controversy over insolvent permit this year… Reduce data manipulation and submission of false data
⑥ 137 days of process mask sales… I stopped the mask upheaval
⑦ Becoming a big star in the pharmaceutical industry… Hanmi Pharm Chairman Seongki Lim dies
⑧ Successive export of technology in Corona 19… The track went up
⑨’Gorgeous debut’… Successful listing of pharmaceutical and bio
⑩ Unfinished botulinum toxin strain wave

⑥ 137 days of public mask sales… I stopped the mask upheaval

It is the’mask’ that cannot be left out when talking about the Corona 19 incident this year. The spread of Corona 19 around the world triggered an unprecedented’mask uprising’, and Korea was no exception.

The KF94 mask, which was usually sold for around 500 won per sheet on the Internet, has once exceeded 4,000 won per sheet due to soaring prices after the Corona 19 incident.

Long lines often lined up all night at large marts where the news of selling masks was reported, and most of the people couldn’t get masks anywhere online or offline, so their feet rolled.

The government introduced the’public mask’ system on March 9 to resolve the unprecedented mask uprising. The public mask system, which allowed one person to purchase two masks once a week through the duplicate purchase confirmation system, sold about 700 million masks for 137 days, and was abolished on June 1.

Some pharmacists complained of extreme fatigue in the first public mask system in history, but pharmacies and other pharmacists were evaluated for reaffirming the public role of pharmacies by playing a role in smooth supply of masks.

⑦ The pharmaceutical industry is a big star… Hanmi Pharm Chairman Seongki Lim dies

In August, Chairman Lim Seong-ki, the’giant’ of the Korean pharmaceutical bio industry and the founder of Hanmi Pharmaceutical Group, passed away with a circle.

The deceased Chairman Lim, who was only 33 years old, founded Hanmi Pharm at the young age and has been running for the past 48 years with a dream of’building a pharmaceutical powerhouse through Korean R&D strategy’.

After the establishment of Hanmi Pharm, Chairman Lim judged that in order to stabilize the company’s sustainable management and develop the domestic pharmaceutical industry, above all, it is necessary to engage in R&D. Track strategy’ has been parallel.

Such steady investment in R&D led to the development of new drugs’Amodipine’ and’Amosartan’ for the first time in the domestic pharmaceutical industry, and was evaluated as having contributed to the development of the domestic pharmaceutical industry as well as a step forward. .

⑧ Successive export of technology in Corona 19… Pharmaceutical·bio storm growth

Technology exports to the domestic pharmaceutical and bio industry were actively carried out even in the midst of the global corona 19 crisis.

According to the Korea Pharmaceutical Bio Association, etc., the annual technology export performance of domestic pharmaceutical and bio companies this year (as of the last 3 days) reached 10.14 trillion won, excluding non-disclosure.

This figure is an increase of more than 20% (1,6322 billion won) compared to 8,5165 billion won (excluding non-disclosure) last year.

It is also worth noting that technology exports from bio companies such as Lego Chem Bio, Future Chem, and Alteogen have been actively carried out. In fact, it was confirmed that most bio-venture companies, except for technology exports such as Hanmi Pharmaceutical, Yuhan Corporation, and JW Holdings, led the technology export performance of the domestic pharmaceutical and bio industry this year.

⑨’Gorgeous debut’… Successful listing of pharmaceutical and bio companies

The IPO fever of domestic pharmaceutical and bio companies was also hot. The IPO market, which was somewhat slow in the first half, regained vitality with the jackpot of SK Biopharm, and in the second half of the year, many pharmaceutical and bio companies were evaluated as having successfully settled in the stock market.

SK Biopharm recorded high competition rates of 835.66 to 1 and 323.03 to 1 in demand forecasting and public offering, respectively, and margins of about 31 trillion won were gathered.

On the first day of listing, the stock price increased by more than four times compared to the public offering price, such as recording a’tasang’ (achieving the upper limit price after the initial price was determined to be twice the public offering price), and recording the upper limit price for two consecutive trading days.

Eoflow, which manufactures medical wearable devices, also attracted attention as it increased by 203.2% from the public offering price (19,000 won) to 57,600 won. Parkcell Bio also recorded a profit of more than five times compared to the public offering price, recording 157,000 won per share.

⑩ Unfinished botulinum toxin strain wave

The conflict between Medytox and Daewoong Pharmaceutical, which has been fighting for several years over the source of the botulinum toxin strain, seemed to seldom end this year.

The US International Trade Commission (ITC) said on the 16th (local time), “The botulinum strain is not a trade secret.” “Nabota” (US product name bulletin) was imported for 21 months after acknowledging only infringement of trade secrets on the manufacturing process. “It is prohibited”, but the nerve war between the two companies continues after that.

Amid an analysis that the ITC issued an ambiguous ruling that was difficult to convince either side of victory and the two companies were providing different commentary, civil and criminal litigation continued in Korea, leading to confrontation between the two sides over the source of the strain. It is expected to continue next year.

【Youth Daily = Reporter Ahn Sang-jun】

– .

Leave a Comment

This site uses Akismet to reduce spam. Learn how your comment data is processed.